Your request to link to rcsb for JAK2/TYK2

• 3LXN: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
• 3LXP: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
• 3NYX: non-phosphorylated tyk2 jh1 domain with quinoline-thiadiazole- thiophene inhibitor (10.1002/PROT.22889 )
• 3NZ0: non-phosphorylated tyk2 kinase with cmp6 (10.1002/PROT.22889 )
• 3ZON: human tyk2 pseudokinase domain bound to a kinase inhibitor
• 4E1Z: structure of mouse tyk-2 complexed to a 3-aminoindazole inhibitor (10.1186/1472-6807-12-22 )
• 4E20: structure of mouse tyk-2 complexed to a 3-aminoindazole inhibitor (10.1186/1472-6807-12-22 )
• 4GFO: tyk2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide (10.1016/J.EJMECH.2013.03.070 )
• 4GIH: tyk2 (jh1) in complex with 2,6-dichloro-n-{2-[(cyclopropylcarbonyl) amino]pyridin-4-yl}benzamide (10.1016/J.EJMECH.2013.03.070 )
• 4GII: tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide (10.1021/JM400266T )
• 4GJ2: tyk2 (jh1) in complex with 2,6-dichloro-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide (10.1021/JM400266T )
• 4GJ3: tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide (10.1021/JM400266T )
• 4GVJ: tyk2 (jh1) in complex with adenosine di-phosphate (10.1016/J.EJMECH.2013.03.070 )
• 4OLI: the pseudokinase/kinase protein from jak-family member tyk2 (10.1073/PNAS.1401180111 )
• 4PO6: crystal structure of the human tyk2 ferm and sh2 domains with an ifnar1 intracellular peptide
• 4PY1: crystal structure of tyk2 in complex with compound 15, 6-((2,5- dimethoxyphenyl)thio)-3-(1-methyl-1h-pyrazol-4-yl)-[1,2,4]triazolo[4, 3-b]pyridazine (10.1016/J.BMCL.2014.07.052 )
• 4WOV: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with bms-066 aka 2-methoxy-n-({6-[3-methyl-7-(methylamino)- 3,5,8,10-tetraazatricyclo[7.3.0.0, 6]dodeca-1(9),2(6),4,7,11-pentaen- 11-yl]pyridin-2-yl}methy l)acetamide (10.1074/JBC.M114.619502 )
• 5C01: crystal structure of kinase (10.1074/JBC.M115.672048 )
• 5C03: crystal structure of kinase (10.1074/JBC.M115.672048 )
• 5F1Z: structure of tyk2 with inhibitor 16: 3-azanyl-5-[(2~{s})-3- methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]- 1~{h}-pyrazolo[4,3-c]pyridin-4-one (10.1021/ACS.JMEDCHEM.5B01857 )
• 5F20: structure of tyk2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1- methylpyrazol-3-yl)-1~{h}-pyrazolo[4,3-c]pyridin-4-one (10.1021/ACS.JMEDCHEM.5B01857 )
• 5TKD: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with 6-[(3,5-dimethylphe nyl)amino]-8- (methylamino) imidazo[1,2-b]pyridazine-3-carbo xamide (10.1039/C6MD00560H )
• 5WAL: identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model (10.1016/J.BMCL.2017.08.022 )
• 6AAM: crystal structure of tyk2 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
• 6DBK: tyk2 with compound 8 (10.1021/ACS.JMEDCHEM.8B00917 )
• 6DBM: tyk2 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
• 6NSL: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-6c aka 6-((1-(4-cyanopheny l)-2-oxo-1,2- dihydro-3-pyridinyl)amino)-n-cyclopropyl-8-(m ethylamino)imidazo[1,2- b]pyridazine-3-carboxamide (10.1021/ACSMEDCHEMLETT.9B00035 )
• 6NZE: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_5 aka 4-[(2-carbamoylphen yl)amino]-6-[(5- fluoropyridin-2-yl)amino]-n-methylpyridine -3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
• 6NZF: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_5 aka 4-[(2-carbamoylphen yl)amino]-6-[(5- fluoropyridin-2-yl)amino]-n-methylpyridine -3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
• 6NZH: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_40 aka 6-cyclopropaneamido-4-[(2- methanesulfonylphenyl)amino]-n-methylpyridine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
• 6NZP: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-11 aka 6-cyclopropaneamido-4-{[2-methoxy-3- (1-methyl-1h-1,2,4-tri azol-3-yl)phenyl]amino}-n-(?h?) methylpyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
• 6NZQ: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_29 aka 6-[(5-fluoro-4-meth ylpyridin-2-yl) amino]-4-({2-methoxy-3-[(pyridin-2-ylmethyl )carbamoyl]phenyl}amino)- n-methylpyridine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
• 6NZR: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_12 aka 4-[(2-methanesulfonylphenyl)amino]-n- (h3)methyl-6-[(pyridin-2- yl)amino]pyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
• 6OVA: crystal structure of tyk2 with novel pyrrolidinone inhibitor (10.1016/J.BMCL.2020.126963 )
• 6VNS: crystal structure of tyk2 kinase with compound 13 (10.1016/J.BMC.2020.115481 )
• 6VNV: crystal structure of tyk2 kinase with compound 14 (10.1016/J.BMC.2020.115481 )
• 6VNX: crystal structure of tyk2 kinase with compound 19 (10.1016/J.BMC.2020.115481 )
• 6VNY: crystal structure of tyk2 kinase with compound 10 (10.1016/J.BMC.2020.115481 )
• 6X8F: crystal structure of tyk2 with compound 11 (10.1021/ACS.JMEDCHEM.0C00948 )
• 6X8G: crystal structure of tyk2 with compound 22 (10.1021/ACS.JMEDCHEM.0C00948 )
• 7AX4: human tyk2 pseudokinase domain (575-869) in complex with 5-(4-fluoro- phenyl)-2-ureido-thiophene-3-carboxylic acid amide (10.1177/24725552211002472 )
• 7K7O: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-12 aka:6-[(cyclopropanecarbonyl)amino]-4-{[2- methoxy-3-(pyrimidin-2-yl)phenyl]amino}-n-methylpyridazine-3- carboxamide (10.1021/ACS.JMEDCHEM.0C01698 )
• 7K7Q: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-12 aka:6-[(cyclopropanecarbonyl)amino]-4-({3- [6-(dimethylcarbamoyl)pyridazin-3-yl]-2-methoxyphenyl}amino)-n- methylpyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.0C01698 )